Physician profile
Bie M Etinge
NPI 1093007890
$5,418.23
in general payments reported to CMS, 2019-2025
38 companies · $704 in 2025
The $704 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $957 · 2021: $1,031 · 2022: $625 · 2023: $724 · 2024: $673 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,101.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,142.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $658.35 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $504.44 | 2020-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $439.74 | 2019-2025 | Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $336.70 | 2019-2022 | |
| Abbvie INC. | $255.59 | 2021-2025 | |
| Dexcom, INC. | $254.13 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $170.60 | 2019-2025 | Verquvo |
| Pfizer INC. | $163.62 | 2019-2021 | |
| Astellas Pharma US INC | $152.82 | 2020-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $152.11 | 2022-2025 | |
| Glaxosmithkline, LLC. | $131.88 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $122.09 | 2020-2021 | |
| Exact Sciences Corporation | $116.41 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $107.44 | 2022-2025 | Repatha, Otezla, Repatha |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bie Etinge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.